A Phase 4 interventional study of Dexmedetomidine and Midazolam in Ultrasound, CT Scans and MRIs, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 28 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2017-03-20.
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures, expected to take more than 30 minutes.
This study was designed to evaluate the safety of a continuous infusion of dexmedetomidine (1 mcg/kg loading dose with 0.6 mcg/kg/hr initial maintenance dose and titrated between 0.2-1.0 mcg/kg/hr) administered to subjects requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures that are expected to take more than 30 minutes.
Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.
First submitted before Hospira became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is ≥28 weeks gestational age and \<17 years of age.
Scheduled for an elective procedure that falls into one of the following three populations:
If female, subject is non-lactating and is either:
Exclusion Criteria:
Subject has bradycardia immediately before dosing, according to respective age group.
Note: Subject can be reassessed after 5 minutes
Subject has hypotension immediately before dosing, according to respective age group.
Note: Subject can be reassessed after 5 minutes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl
0.1 - 1.0 mcg/kg/hr IV
0.025 - 2 mg/kg IV
0.5 - 3 mcg/kg IV
Number of Subjects Who Had Success in Sedation
Success in sedation was defined by a combined endpoint which was the combination of the following: 1. Subject had adequate level of sedation (University of Michigan Sedation Scale \[UMSS\] score between 1 to 3 \[minimally sedated to deeply sedated\] or Neonatal Pain, Agitation and Sedation Scale \[N-PASS\] score between -5 to -2 \[Light sedation\]) at least 80% of the time the subject was given the study drug. 2. Subject had successfully completed the procedure without a need for rescue sedation (Midazolam). 3. Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status
Time frame: From baseline to end of post-treatment period (approximately 24 hours)
Number of Subjects Not Receiving Rescue Midazolam
Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.
Time frame: During the treatment period, up to approximately 24 hours
Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention
Time frame: During the treatment period, up to approximately 24 hours
Number of Subjects Who Were Adequately Sedated at Least 80% of Time
Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug
Time frame: During the treatment period, up to approximately 24 hours
Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion
Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion
Time frame: During the treatment period, up to approximately 24 hours
Frequency of Midazolam Required for Sedation
Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).
Time frame: During the treatment period, up to approximately 24 hours
Frequency of Fentanyl Use for Analgesia
Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.
Time frame: During the treatment period, up to approximately 24 hours
Total Amount of Rescue Sedation (Midazolam)
Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure
Time frame: During the treatment period, up to approximately 24 hours
Total Amount of Rescue Analgesia (Fentanyl)
Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure
Time frame: During the treatment period, up to approximately 24 hours
Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication
Time frame: During the treatment period, up to approximately 24 hours
| Milestone | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Started | 1 | 89 |
| Completed | 1 | 81 |
| Not completed | 0 | 8 |
| Withdrew: Diagnostic/therapeuticprocedurecompleted | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Medical condition changes&deep sedation | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
Success in sedation was defined by a combined endpoint which was the combination of the following: 1. Subject had adequate level of sedation (University of Michigan Sedation Scale \[UMSS\] score between 1 to 3 \[minimally sedated to deeply sedated\] or Neonatal Pain, Agitation and Sedation Scale \[N-PASS\] score between -5 to -2 \[Light sedation\]) at least 80% of the time the subject was given the study drug. 2. Subject had successfully completed the procedure without a need for rescue sedation (Midazolam). 3. Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=1, 40) | 0 | 2 |
| MIDTP (n=0, 25) | 0 | 0 |
| Surgical procedures (n=0, 12) | 0 | 0 |
Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=1, 40) | 1 | 12 |
| MIDTP (n=0, 25) | 0 | 5 |
| Surgical procedures (n=0, 12) | 0 | 1 |
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=1, 40) | 1 | 37 |
| MIDTP (n=0, 25) | 0 | 19 |
| Surgical procedures (n=0, 12) | 0 | 12 |
Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=1, 40) | 0 | 21 |
| MIDTP (n=0, 25) | 0 | 7 |
| Surgical procedures (n=0, 12) | 0 | 2 |
Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion
| Hours | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=1, 40) | NA | 23.5 (16.00 to 28.00) |
| MIDTP (n=0, 25) | NA | 20.00 (17.00 to 34.00) |
| Surgical procedures (n=0, 12) | NA | 20.00 (15.00 to 25.00) |
Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).
| Occurrence | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=0, 28) | — | 2 (1 to 4) |
| MIDTP (n=0, 20) | — | 1 (1 to 2) |
| Surgical procedures (n=0, 11) | — | 1 (1 to 2) |
Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.
| Occurrence | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=0, 6) | — | 1 (1 to 3) |
| MIDTP (n=0, 22) | — | 1 (1 to 5) |
| Surgical procedures (n=0, 12) | — | 2.50 (1 to 5) |
Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure
| milligram | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=0, 28) | — | 2.62 ± 1.611 |
| MIDTP (n=0, 20) | — | 1.70 ± 0.767 |
| Surgical procedures (n=0, 11) | — | 2.45 ± 0.907 |
Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure
| microgram | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=0, 6) | — | 10.83 ± 8.010 |
| MIDTP (n=0, 22) | — | 61.86 ± 65.740 |
| Surgical procedures (n=0, 12) | — | 104.83 ± 72.007 |
| Participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| NIDTP (n=1, 40) | 0 | 0 |
| MIDTP (n=0, 25) | 0 | 0 |
| Surgical procedures (n=0, 12) | 0 | 2 |
Collected over Non-serious adverse events from start of study drug administration until 24(±12) hours following study drug discontinuation. Reported serious adverse events from the time the subject signed informed consent until 30 days after study drug discontinuation.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | — | 0/1 (0%) | 1/1 (100%) |
| Dose Level 2 | — | 1/89 (1.1%) | 66/89 (74.2%) |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| SyncopeNervous system disorders | 0/1 | 1/89 |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Respiratory depressionRespiratory, thoracic and mediastinal disorders | 1/1 | 53/89 |
| HypotensionVascular disorders | 0/1 | 37/89 |
| BradycardiaCardiac disorders | 0/1 | 4/89 |
| Blood pressure systolic decreasedInvestigations | 0/1 | 3/89 |
| HeadacheNervous system disorders | 0/1 | 3/89 |
| NauseaGastrointestinal disorders | 0/1 | 2/89 |
| VomitingGastrointestinal disorders | 0/1 | 2/89 |
| Blood pressure diastolic decreasedInvestigations | 0/1 | 2/89 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/1 | 2/89 |
| HypertensionVascular disorders | 0/1 | 2/89 |
Safety Evaluable Population: All subjects who receive any amount of study drug. All safety analyses will be performed on this population.
| Age, Continuous(years) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Mean | 0.1 (0.1 to 0.1) | 7.97 (0.3 to 17.3) | 7.89 (0.1 to 17.3) |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Female | 0 | 41 | 41 |
| Male | 1 | 48 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 23 | 23 |
| Not Hispanic or Latino | 1 | 66 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 22 | 23 |
| White | 0 | 60 | 60 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 6 | 6 |
The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Hospira, now a wholly owned subsidiary of Pfizer →